3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Sarcoma
5
Carcinoma, Non-Small-Cell Lung
5
Rhabdomyosarcoma
4
Prostatic Neoplasms
4
Osteosarcoma
3
Neoplasms
3
Sarcoma, Synovial
2
Sarcoma, Ewing
2
Neuroectodermal Tumors, Primitive, Peripheral
2
Neoplasm Metastasis
2
Lung Neoplasms
2
Head and Neck Neoplasms
2
Colorectal Neoplasms
2
Carcinoma, Hepatocellular
2
Breast Neoplasms
2
Adrenocortical Carcinoma
2
Wilms Tumor
1
Uveal Melanoma
1
Squamous Cell Carcinoma of Head and Neck
1
Small Cell Lung Carcinoma
1
Retinoblastoma
1
Rectal Neoplasms
1
Neuroendocrine Tumors
1
Neuroectodermal Tumors, Primitive
1
Neuroectodermal Tumors
1
Neuroblastoma
1
Mesothelioma, Malignant
1
Liver Neoplasms
1
Liposarcoma
1
Leiomyosarcoma
1
Interventions
Oxaliplatin
146
Fluorouracil
137
Capecitabine
122
Leucovorin
106
Irinotecan
85
Radiotherapy
67
Bevacizumab
64
Cetuximab
46
Folfox protocol
28
Surgical Procedures, Operative
23
Radiation
23
Drug Therapy
22
Panitumumab
19
XELOX
18
Chemotherapy, Adjuvant
15
Neoadjuvant Therapy
14
Radiotherapy, Intensity-Modulated
13
Chemoradiotherapy
13
Magnetic Resonance Spectroscopy
11
regorafenib
10
Nivolumab
10
Floxuridine
10
sintilimab
8
raltitrexed
8
Specimen Handling
8
IFL protocol
8
Celecoxib
8
Biopsy
8
trifluridine tipiracil drug combination
7
tislelizumab
7
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Rectal Neoplasms
×
cixutumumab
×
Clear all
NCT00845039
2018-07-02
FC-4
Eli Lilly and Company
Phase 2
Terminated
4 enrolled
9 charts